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Abstract
Background: Bipolar disorder (BD) is a serious and recurring condition that affects approximately 2.4% of the global population. 
About half of BD sufferers have an illness course characterized by either a manic or a depressive predominance. This 
predominant polarity in BD may be differentially associated with several clinical correlates. The concept of a polarity index (PI) 
has been recently proposed as an index of the antimanic versus antidepressive efficacy of various maintenance treatments for 
BD. Notwithstanding its potential clinical utility, predominant polarity was not included in the DSM-5 as a BD course specifier.
Methods: Here we searched computerized databases for original clinical studies on the role of predominant polarity for 
selection of and response to pharmacological treatments for BD. Furthermore, we systematically searched the Pubmed 
database for maintenance randomized controlled trials (RCTs) for BD to determine the PI of the various pharmacological 
agents for BD.
Results: We found support from naturalistic studies that bipolar patients with a predominantly depressive polarity are more 
likely to be treated with an antidepressive stabilization package, while BD patients with a manic-predominant polarity are 
more frequently treated with an antimanic stabilization package. Furthermore, predominantly manic BD patients received 
therapeutic regimens with a higher mean PI. The calculated PI varied from 0.4 (for lamotrigine) to 12.1 (for aripiprazole).
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Conclusions: This review supports the clinical relevance of predominant polarity as a course specifier for BD. Future studies 
should investigate the role of baseline, predominant polarity as an outcome predictor of BD maintenance RCTs.
Keywords: bipolar disorder, maintenance, polarity index, predominant polarity, treatment
Introduction
Bipolar disorder (BD) is a chronic and debilitating mental dis-
order that affects approximately 2.4% of the general popula-
tion (Belmaker, 2004; Merikangas et al., 2011). Bipolar disorder 
is associated with an increased risk of mortality due to suicide 
(Gonda et al., 2012) and co-morbid general medical conditions, 
mainly cardio-metabolic diseases (Fagiolini et al., 2008; Weiner 
et al., 2011). Bipolar disorder is characterized by recurring major 
depressive, manic (or hypomanic), and mixed episodes (Phillips 
and Kupfer, 2013). Lewis Judd and coworkers (2002, 2003) at the 
National Institute of Mental Health rated the affective symp-
toms of BD type I  and II patients on a weekly basis. These 
authors demonstrated that BD patients spend approximately 
half of their lifetime symptomatic, mostly with depressive epi-
sodes/symptoms. However, germane to this thesis, the course of 
“manic depressive insanity” has been noted to be characterized 
by significant inter-individual variation (Kraepelin, 1921).
In the early 1960s, Leonhard collected data from 117 manic-
depressive patients. Predominantly manic symptoms occurred 
in 17.9% of patients, while 25.6% presented with a predomi-
nantly depressive clinical course, and 56.4% had equally pro-
nounced mania and depression (Leonhard, 1963). Angst (1978) 
collected data from a sample of 95 manic-depressive inpatients 
from 1959 to 1975. Based on this survey, Angst initially proposed 
the concept of predominant polarity. He observed that some 
patients have a nuclear type of illness (i.e. patients who show 
both mania and depression requiring hospital admission), while 
some patients have predominantly depressive (i.e. the patient 
required hospitalization for depression but had only hypoma-
nia) or manic (the patient required hospitalizations for mania, 
but had no or minor depression; Angst, 1978).
Recently, a renewed interest in the topic of predominant 
polarity as a course specifier for BD emerged in the literature, 
driven at least in part by a corresponding observation of the dif-
ferential effects of newly-discovered bipolar agents on manic 
and depressive features (Osher et al., 2000; Colom et al., 2006; 
Rosa et al., 2008; Colom and Vieta, 2009; Baldessarini et al., 2012). 
Colom and colleagues (2006) proposed a threshold of at least 
two-thirds of lifetime depressive episodes for the definition of 
a depressive-predominant polarity, while at least two-thirds of 
past episodes would fulfill the criteria for mania/hypomania 
and define a manic-predominant polarity. However, the working 
definitions for predominant polarity have varied across studies 
(Osher et al., 2000; Daban et al., 2006; Baldessarini et al., 2012). 
Slightly more than half of BD patients exhibit a specific predom-
inant polarity, while a significant proportion of BD patients have 
an undetermined predominant polarity.
A previous review suggested that the depressive-predom-
inant polarity is more common than the manic-predominant 
polarity (Colom and Vieta, 2009). However, studies which incor-
porated exclusively type I BD patients found the opposite pat-
tern (i.e. a higher prevalence of the manic-predominant polarity; 
Osher et al., 2000; Mazzarini et al., 2009; Pacchiarotti et al., 2011; 
Baldessarini et al., 2012). A confounder is that patterns of refer-
ral to tertiary centers where such studies are done reflect clinical 
acuity rather than community prevalence, providing a source of 
bias in such analyses.
Clinically-relevant correlates and outcomes for BD may be 
predicted by specific predominant polarity (i.e. depressive vs. 
manic). Depressive-predominant polarity has been associated 
with a depressive onset of illness (Rosa et al., 2008; Forty et al., 
2009; Baldessarini et al., 2012), a delayed diagnosis of BD (Rosa 
et al., 2008; Baldessarini et al., 2012), type II BD, and an increased 
risk for suicidal acts (Colom et al., 2006; Gonzalez-Pinto et al., 
2010; Baldessarini et al., 2012). Conversely, manic-predominant 
polarity is associated with a younger onset of illness (Gonzalez-
Pinto et  al., 2010; Baldessarini et  al., 2012), a manic/psychotic 
first episode (Forty et al., 2009; Baldessarini et al., 2012), and a 
higher rate of substance abuse prior to the first episode (Colom 
et al., 2006; Popovic et al., 2014). Furthermore, a recent system-
atic review identified that a depressive-predominant polarity 
may be associated with a higher number of mixed episodes and 
with the presence of melancholic features (Carvalho et al., 2014).
Although a previous International Society of Bipolar 
Disorders (ISBD) taskforce on the nomenclature and course of 
bipolar disorder had concluded that the clinically-derived pre-
dominant polarity construct developed by Angst (1978) and 
operationalized by Colom et al. (2006) is a valid course specifier 
for BD, the recently-released DSM-5 did not include this concept 
in the criteria for bipolar disorders (APA, 2013). Current views 
on psychiatric nosology assert that clinical utility should guide 
validity (McGorry, 2013). Emerging evidence indicates that the 
concept of predominant polarity may influence the selection of 
maintenance pharmacological (Popovic et al., 2012, 2013; Nivoli 
et al., 2013) and psychological treatments (Popovic et al., 2013) 
for BD. Furthermore, the polarity index metric has been recently 
proposed to rank maintenance treatments for BD based on the 
relative antidepressive versus antimanic efficacies of interven-
tions (Popovic et al., 2012).
In keeping with this view, the overarching aim of this article 
was to review the extant evidence on the possible clinical utility 
of the concept of predominant polarity for treatment selection 
in BD. Furthermore, we present clinical perspectives to high-
light practical implications of predominant polarity. Limitations 
of the available evidence are also discussed. Finally, a research 
agenda is proposed.
Methods
A search was conducted using Pubmed/MEDLINE, EMBASE, and 
Web of Science computerized databases from inception of the 
project to December 8th, 2013. Search terms included polarity 
index, polarity, treatment, maintenance, predominant polarity, 
and bipolar disorder. Original studies on the treatment impli-
cations of predominant polarity (or the polarity index) were 
included in this comprehensive review.
Popovic and coworkers (2012) previously calculated the 
polarity index of maintenance pharmacological treatments 
of bipolar disorder based on a comprehensive search of data 
derived from randomized controlled trials (RCTs). In this report, 
we comprehensively searched the Pubmed/MEDLINE database 
for new maintenance RCTs of pharmacological treatments for 
BD from inception up to January 10th, 2014. The recalculated 
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polarity indexes of each drug (whether approved or not by regu-
latory agencies) are presented. The search terms bipolar disor-
der, mixed, mania, and bipolar depression were co-referenced 
with the term maintenance and the generic names of sub-
stances. Eligible studies were randomized, double-blind studies 
which compared mood stabilizers or antipsychotic drugs, alone 
or in combination with standard mood-stabilizing medications 
(e.g. lithium and valproate), with a placebo comparator. Included 
studies had a minimal duration of 24 weeks, in patients aged 
≥18 years old. Exclusion criteria included small sample size (i.e. 
a median sample size <16.5 participants in each group; Popovic 
et al., 2012), a sample not exclusively composed of BD partici-
pants, and the lack of a placebo control. A manual search of ref-
erence lists of included studies augmented the search protocol. 
The citation tracking of included RCTs was searched in Google 
Scholar. No language restrictions were applied in this review.
The Concept of Polarity Index
Number needed to treat (NNT) is an effect size measure that 
is a recommended tool to summarize the results of BD trials 
(Martinez-Aran et al., 2008; Ketter et al., 2011). NNT can quantify 
the clinical relevance of a statistically significant trial outcome 
(Citrome, 2008). According to the most recent version of the 
CANMAT (Canadian Network for Mood and Anxiety Treatments) 
guidelines for the management of BD (Yatham et al., 2013), cur-
rent first-line drug treatments for BD are: lithium, lamotrigine, 
divalproex, olanzapine, quetiapine, risperidone long-acting 
injection (LAI), aripiprazole, and the adjunctive use (with lith-
ium or divalproex) of quetiapine, risperidone LAI, aripiprazole, 
or risperidone. It is noteworthy that some of these drugs are 
efficacious in preventing depressive episodes, but have lim-
ited efficacy for the prevention of manic episodes (for example, 
lamotrigine), while other drugs have a greater efficacy for the 
prevention of manic recurrences/relapses and a limited efficacy 
for the prophylaxis of major depressive episodes (for example, 
aripiprazole). Based on this fact, the concept of a polarity index 
(PI) was recently proposed (Popovic et al., 2012) as an attempt to 
rank the relative antimanic versus antidepressive prophylactic 
efficacy of distinct maintenance treatments for BD.
The PI is calculated by dividing the NNT for the prevention of 
depressive episodes by the NNT for the prevention of manic epi-
sodes (Popovic et al., 2012). Accordingly, an agent with a PI equal 
to 1 would have a balanced efficacy in the prophylaxis of both 
depressive and manic episodes. A drug with a PI > 1 would have 
stronger antimanic versus antidepressive prophylactic proper-
ties, while those with a PI < 1 are more effective in preventing 
depressive episodes than manic relapses/recurrences.
Polarity Index of Maintenance Pharmacological 
Treatments for BD
Our systematic search identified 19 potentially-eligible main-
tenance trials for BD. A  clinical trial compared the efficacy of 
lamotrigine + placebo versus lamotrigine + divalproex for the 
prevention of depressive recurrences in 86 types I  and II BD 
participants (Bowden et al., 2012). However, this study did not 
provide data on the prevention of (hypo) manic relapses. Thus, 
the polarity index could not be calculated. A recent RCT stud-
ied the effects of adjunctive N-acetlycysteine (NAC; 2 g/day) as 
maintenance treatment for BD (Berk et  al., 2012). Participants 
were initially screened for bipolar depression and had received 
adjunctive NAC for 8 weeks (open-label phase); by the end of 
the acute phase all participants could be randomized to either 
NAC or placebo for 24 weeks. These participants had low base-
line symptoms, and the relatively low rates of recurrences pos-
sibly prevented the detection of drug differences. The authors 
concluded that the trial was a failed study instead of a negative 
one (Berk et al., 2012). Therefore, due to these limitations, this 
work was not included in this review. Two additional RCTs were 
identified in this updated systematic review and met inclusion 
criteria (Woo et al., 2011; Berwaerts et al., 2012). Thus, 18 studies 
satisfied inclusion criteria.
All investigations had an acute treatment phase, followed by 
a double-blind, controlled, maintenance phase. Some RCTs used 
a three-arm design: therefore, two comparisons were possible 
in these circumstances. Characteristics of included studies are 
summarized in Table 1.
The NNTs for the prevention of manic and depressives epi-
sodes for each agent, as well as the polarity index of each agent, 
are depicted in Table 2.
A predominantly antimanic polarity index was observed for 
aripiprazole monotherapy (PI = 12.1; Keck et al., 2007), followed 
by risperidone LAI (Quiroz et al., 2010; Vieta et al., 2012), aripipra-
zole adjunctive to lithium or divalproex (Marcus et al., 2011; Woo 
et al., 2011), olanzapine monotherapy (Tohen et al., 2006; Vieta 
et  al., 2012), ziprasidone adjunctive to lithium or divalproex 
(Bowden et  al., 2010), adjunctive risperidone LAI (Macfadden 
et al., 2009), and lithium (Prien et al., 1973; Bowden et al., 2000, 
2003; Calabrese et al., 2003; Weisler et al., 2011). A polarity index 
favoring efficacy for the prevention of depressive episodes was 
observed for lamotrigine (pooled PI = 0.4; Bowden et al., 2003; 
Calabrese et  al., 2003), followed by olanzapine combined with 
lithium or divalproex (Tohen et  al., 2004), divalproex (Bowden 
et al., 2000), and oxcarbazepine combined with lithium (Vieta, 
Cruz, et al., 2008). Adjunctive quetiapine (Vieta, Suppes, et al., 
2008; Suppes et al., 2009) and quetiapine monotherapy (Weisler 
et  al., 2011) had polarity indexes closest to unit, suggesting a 
more balanced efficacy for the prevention of both manic and 
depressive recurrences.
Although the primary focus of this review is on the relation-
ships of predominant polarity (and polarity index) for the selec-
tion of maintenance drug treatments for BD, it is noteworthy 
that a recent systematic review also determined the polarity 
index for evidence-based maintenance psychological interven-
tions for BD (Popovic et  al., 2013). In brief, most psychosocial 
interventions had a polarity index <1, indicating better efficacy 
for the prevention of depressive episodes, including cognitive 
behavioral therapy (PI ranging from 0.33 to 0.89), family-focused 
therapy (PI = 0.42), and psychoeducation (PI ranging from 0.73 to 
0.78). Enhanced relapse prevention was equally effective for the 
prevention of depressive and manic episodes (PI = 1.0), whereas 
brief-technique driven interventions (PI  =  3.36) and caregiver 
group psychoeducation (PI = 1.78) were more efficacious for the 
prevention of manic episodes (Popovic et al., 2013).
Clinical Studies on Predominant Polarity
This review had identified three original clinical studies in which 
the concept of predominant polarity was investigated either as 
a post hoc predictor of clinical response (Vieta et al., 2009) or as 
specifier associated with the selection of specific somatic treat-
ments for BD (Nivoli et al., 2013; Popovic et al., 2014). These stud-
ies are summarized in Table 3.
A post hoc analysis of a previously published 8-week multi-
center RCT which compared the olanzapine-fluoxetine combi-
nation with either olanzapine alone or placebo for the treatment 
of bipolar I  depression (Tohen et  al., 2003) investigated the 
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Table 2. Number Needed to Treat for the Prevention of Manic and Depressive Episodes and Polarity Index of Drugs Used for Maintenance treat-
ment of Bipolar Disorder.
Treatment NNT mania NNT depression Polarity Index
Aripiprazole monotherapy (Keck et al., 2007) 7.0 73.0 10.4
Aripiprazole adjunctive to lithium/divalproex-pooled (Marcus et al., 2011; 
 Woo et al., 2011)
9.0 38.0 4.2
Lamotrigine-pooled (Bowden et al., 2003; Calabrese et al., 2003) 50.4 20.2 0.4
Lithium-pooled (Prien et al., 1973; Bowden et al., 2000, 2003;  
Calabrese et al., 2003; Weisler et al., 2011)
4.4 6.1 1.4
Olanzapine monotherapy-pooled (Tohen et al., 2006; Vieta et al., 2012) 4.4 17.5 4.0
Olanzapine combined with lithium/divalproex (Tohen et al., 2004) 11.2 6.2 0.5
Oxcarbazepine combined with lithium (Vieta et al., 2008) 8.2 5.1 0.6
Quetiapine monotherapy (Weisler et al., 2011) 2.4 3.3 1.4
Quetiapine combined with lithium/divalproex-pooled (Vieta et al., 2008;  
Suppes et al., 2009)
7.1 5.9 0.8
Risperidone LAI monotherapy-pooled (Quiroz et al., 2010; Vieta et al., 2012) 4.0 36.3 9.1
Adjunctive risperidone LAI (Macfadden et al., 2009) 7.9 15.8 2.0
Divalproex (Bowden et al., 2000) 21.3 10.5 0.5
Ziprasidone Adjunctive to lithium/divalproex (Bowden et al., 2010) 14.1 55.1 3.9
Paliperidone ER (Berwaerts et al., 2012) 8.0 17.0 N/A
NNT values in italic are negative, indicating that placebo was more effective than active treatment, although results of original trials did not reach statistical signifi-
cance. When more than one RCT was available for a given treatment, calculations represent pooled results. LAI, long-acting injection; N/A, could not be calculated 
accurately as the NNT for the prevention of depression is negative; NNT, number needed to treat; RCT, randomized controlled trials.
relationship of predominant polarity as defined by a threshold 
of ≥2/3 of lifetime affective episodes of a given polarity (Colom 
et  al., 2006) on treatment response (Vieta et  al., 2009). Of the 
833 participants initially enrolled in the trial, 788 subjects had 
both baseline and follow-up ratings so as to allow final outcome 
assessments; of these patients, 367/788 (46.6%) could be cate-
gorized as having had either a depressive-predominant polar-
ity (269/788; 34.1%) or a manic-predominant polarity (98/788; 
12.4%). The primary measure was a change in the Clinical Global 
Impression of severity of major depression (CGI-D; Spearing 
et al., 1997). The effect of predominant polarity as an outcome 
predictor was markedly dissimilar between men and women. In 
women there were no significant differences in CGI-D scores in 
accordance with predominant polarity (i.e. manic versus depres-
sive), whereas in men the predominantly manic group has a sig-
nificantly better outcome when compared to the predominantly 
depressive group. Furthermore, predominantly manic men had 
better outcomes compared to women with both predominant 
polarity types (Vieta et al., 2009).
The prescription patterns of a sample of 604 DSM-IV-TR BD 
patients attending the Bipolar Unit of Barcelona were investi-
gated in a naturalistic study. A  principal component analysis 
showed three factors: (i) an antimanic stabilization package, 
which was characterized by the use of classic thymoleptic 
medications (i.e. lithium, valproate, and carbamazepine), three 
atypical antipsychotics (clozapine, risperidone, and olanzapine), 
and electroconvulsive therapy; (ii) an antidepressive stabiliza-
tion package, which included lamotrigine and other atypical 
antipsychotic agents (notably quetiapine); and (iii) an anti-bipo-
lar II package, which included diverse antidepressants. Bipolar 
patients with a predominantly manic polarity were treated 
mainly with the antimanic stabilization package, whereas BD 
patients with a depressive-predominant polarity were more fre-
quently treated with the antidepressive stabilization package 
(Nivoli et al., 2013). The anti-bipolar II package included mainly 
type II BD patients with a depressive-predominant polarity 
(Nivoli et al., 2013).
Popovic and colleagues (2014) studied a sample of 604 DSM-
IV-TR BD patients, of which 257 presented a clear predominant 
polarity type (n  =  143; 55.6% had a depressive-predominant 
polarity and n  =  114; 44.4% had a manic-predominant polar-
ity; Colom et  al., 2006). The total polarity index (calculated as 
mean value of polarity index of all prescribed mood stabilizers 
and antipsychotics in each patient) were significantly higher in 
the predominantly manic group. Moreover, the polarity index 
of antipsychotics and mood stabilizers taken separately were 
also higher in the manic-predominant polarity group. The use 
of antidepressants, lamotrigine, and benzodiazepines was 
more prevalent in the depressive-predominant polarity group 
(Popovic et al., 2014).
D2 Receptor Binding Affinity and Polarity Index of 
Atypical Antipsychotics
Brugue and Vieta (2007) had previously hypothesized that a 
lower D2 receptor occupancy would be more more relevant 
than a greater 5-HT(2) receptor action to the efficacy of atypi-
cal antipsychotics for the acute treatment of bipolar depression 
Herein we examined the relationship of D2 receptor affinities 
(Richtand et al., 2007) and the polarity index of atypical antip-
sychotrics in monotherapy (Table 4). Overall, we found that the 
higher the D2 receptor binding affinity, the lower the PI of dif-
ferent atypical antipsychotics in monotherapy. Aripiprazole did 
not seem to follow the same pattern: in fact, the mechanism of 
action of aripiprazole is rather complex (Mailman and Murthy, 
2010). Once thought to primarily act as a partial agonist at D2 
receptors, new data support that aripiprazole may act either 
as an antagonist or as an agonist at distinct subpopulations of 
D2 receptors in a process referred to as functional selectivity 
(Mailman and Murthy, 2010). These unique mechanisms may 
explain the divergent findings related to D2 binding affinity and 
the PI of this compound.
Clinical Perspectives
In spite of the fact that the efficacy of antidepressant drugs for the 
acute and maintenance treatment of BD is one of the most long-
standing controversial topics in the literature (Gitlin, 2012; Malhi, 
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Table 4. Polarity Index Based on Monotherapy of Atypical Antipsychotics and Dopamine D2 Receptors.
Drug NNT Depression NNT Mania Polarity Index Ki (nM)*
Aripiprazolea 73.0 7.0 10.4 0.95
Risperidone (LAI)b 36.3 4.0 9.1 4.9
Olanzapinec 17.5 4.4 4.0 72
Quetiapined 2.4 3.3 1.4 567
*Ki values obtained from Richtand et al. (2007); 
aData from Keck et al. (2007); bData from Quiroz et al. (2010) and Vieta et al. (2012); cData pooled from Tohen et al. (2006) 
and Vieta et al. (2012); dData obtained from Vieta et al. (2012). Ki, dissociation constant; LAI, long-acting injection; NNT, number needed to treat.
Table 3. Characteristics and Main Finsdings of Clinical Studies on Predominant Polarity (PP).
Reference Sample characteristics Study Design
Definition of predominant 
polarity Main Findings
Vieta et al., 2009 833 type I BD participants in 
a depressive episode; 788 
had baseline and follow-up 
ratings; DSM-IV criteria
Multicenter RCT
Olanzapine, OFC and placebo
≥2/3 of lifetime episodes of a 
given polarity
34.1% (n = 269) had a DPP 
and 12.4% (n = 98) had a 
MPP. Psychotic features 
were more common in 
the DPP. Rapid cycling was 
more common in the MPP 
(only in men). In men, a 
MPP was associated with 
a greater likelihood for 
acute treatment response.
Nivoli et al., 2013 604 BD participants (types I, II 
and NOS); DSM-IV; 332 (55%) 
were females; 407 (67.4%) had 
type I BD and 201 (32.6%) had 
type II or type NOS BD; 314 
(52.0%) had experienced a 
psychotic mood episode and 
117 (19.4%) had rapid cycling; 
Spain
Observational ≥2/3 of lifetime episodes of a 
given polarity
Principal component 
analysis revealed that 3 
basic treatment packages: 
antimanic stabilization 
package, antidepressant 
stabilization package, 
and anti-bipolar II 
package. Antimanic 
stabilization package was 
associated with a MPP, 
while the antidepressant 
stabilization package was 
associated with the DPP.
Popovic et al., 
2013
604 type I or II BD participants; 
included 257 participants with 
a PP; DSM-IV-TR; Spain
Observational ≥2/3 of lifetime episodes of a 
given polarity
44.4% (n = 114) had a MPP 
and 55.6% (n = 143) had a 
DPP. Polarity index of the 
therapeutic regimen was 
significantly higher for 
the MPP group. The MPP 
group had higher use of 
olanzapine, risperidone, 
and typical antipsychotics. 
The DPP group had 
higher use of lamotrigine, 
antidepressants TCAs, 
SSRIs, SNRIs, and 
benzodiazepines. The MPP 
group had significantly 
younger age of disease 
onset, younger age at first 
hospitalization, and higher 
hospitalization rate.
BD, bipolar disorder; DPP, depressive-predominant polarity; MPP, manic-predominant polarity; OFC, olanzapine-fluoxetine combination; RCT,; SSRIs, selective seroto-
nina reuptake inhibitors; SNRIs, selective norepinephrine reuptake inhibitors; TCAs, trycyclic antidepressants.
2012), in part due to an inconsistent evidence base (Vazquez et al., 
2011), epidemiological surveys indicate that antidepressant drugs are 
widely employed in the management of BD, mainly for the manage-
ment of acute bipolar depression episodes (Post et al., 2011; Grande 
et al., 2013; Llorca et al., 2013). This status quo resulted in a recent ISBD 
consensus panel on the use of antidepressant in BD (Pacchiarotti 
et al., 2013), based to a large degree on expert consensus through the 
Delphi method. However, the evidence reviewed thus far suggests 
that clinicians from tertiary mood disorder services consider the 
patient’s predominant polarity while prescribing antidepressants.
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Given the extant evidence base showing that maintenance 
agents differ in their efficacy across the two poles, the predomi-
nant polarity of a given patient is probably considered by clini-
cians more broadly when selecting both acute and long-term 
maintenance treatments. As stated before, there are concerns 
regarding the use of antidepressants for the long-term treat-
ment of BD. Notwithstanding concerns about the so-called 
antidepressant-induced manic switch, this aspect remains con-
troversial, as a clear causal relationship linking antidepressant 
exposure to the precipitation of mania is not firmly established 
(Licht et al., 2008).
Discussion
Predominant polarity predicts several clinical correlates in BD, 
as reviewed elsewhere (Colom and Vieta, 2009; Baldessarini 
et al., 2012). The present review strongly suggests that the con-
cept of predominant polarity is useful for the selection of appro-
priate maintenance treatments for BD. In keeping with this view, 
it is important to consider that one should consider the clinical 
utility of a given specifier to endorse its inclusion in current psy-
chiatric nosology (McGorry, 2013).
This review demonstrates that different maintenance drug 
treatments for BD may have differential efficacies for the pre-
vention of manic versus depressive episodes. This systematic 
literature search updates a previous review (Popovic et al., 2012). 
We had identified two additional eligible RCTs (Woo et al., 2011; 
Berwaerts et al., 2012). Importantly, paliperidone’s PI could not 
be calculated, as the NNT for the prevention of depressive epi-
sodes was negative. Hence, most atypical antipsychotics have 
a greater efficacy for the prevention of manic episodes, while 
quetiapine has a more balanced efficacy for the maintenance 
treatment of BD.
The published post hoc analysis of the 8-week RCT, which 
studied the olanzapine-fluoxetine combination versus both 
olanzapine alone and placebo in the acute treatment of bipolar 
depression (Vieta et al., 2009), found that a manic-predominant 
polarity predicted efficacy specifically for male participants. 
While these data suggest that predominant polarity may influ-
ence acute treatment responses in BD, the limitations of this 
study do not allow the establishment of firm directions. In fact, 
most patients in that trial had a 2.7-fold excess for the depres-
sive-predominant polarity when compared to a manic-predom-
inant polarity, as expected from a recruited sample for a bipolar 
depression trial. Furthermore, this post hoc analysis could not 
include all participants of the original trial (Tohen et al., 2003). 
Thus, one might argue that this analysis did not have adequate 
power to detect additional inferences, as acknowledged by the 
authors (Vieta et al., 2009). Consequently, the role of predomi-
nant polarity for the prediction of acute treatment responses in 
BD remains, to a large extent, an open question.
Two naturalistic clinical studies from the same research 
group (Nivoli et al., 2013; Popovic et al., 2014) suggest that the 
concept of predominant polarity may play a decisive role for 
the selection of maintenance pharmacological treatments for 
BD. The first report showed that patients with a predominantly 
manic polarity would be treated in the majority circumstances 
with an antimanic stabilization package, while patients with a 
depressive-predominant polarity would be mainly treated with 
an antidepressive stabilization package (Nivoli et al., 2013). The 
other study viewed the data from a different angle. Patients with 
a manic-predominant polarity were treated with a therapeutic 
regimen with a higher mean polarity index, while patients with 
a depressive-predominant polarity were treated with agents 
with an overall lower PI (Popovic et al., 2014). Despite the fact 
that these data may provide some support for the wise everyday 
care of BD, it should be interpreted in light of several limitations. 
First, the data came from a single center (i.e. the Barcelona BD 
Center). Thus, these data may not reflect the practice at other 
centers or settings. Furthermore, part of the data was collected 
retrospectively. Therefore, it should be replicated in prospective 
multi-center studies to establish more conclusive evidences on 
the true role of predominant polarity (and the PI) for the selec-
tion of maintenance treatments for BD. Lastly, there is a degree 
of circularity in the argument: clinicians choose treatments they 
believe to be most useful for an individual’s pattern of illness, 
and it is unsurprising that prescription patterns reflect this.
Although intuitive and easy-to-use, the PI has been criticized 
as imperfect by some investigators (Alphs et al., 2013). First, the 
PI does not offer a credible interval. Second, there are variations 
in clinical and socio-demographic characteristics of included 
participants across different trials (for example, age, sex, previ-
ous exposure to treatment, comorbidities, number of previous 
affective episodes, etc). Third, the calculation of the PI would be 
impossible when confidence intervals of NNTs for the preven-
tion of either depressive or manic episodes includes zero. Lastly, 
it is relativistic, not absolute; an agent that has both potent anti-
manic and anti-depressive effects would have the same PI as 
an agent weak in both poles. We agree with the authors that no 
simple metric is sufficient for the complex evidence-based final 
choice of a given maintenance treatment for BD. For instance, 
consider that a drug with a NNT for prevention of mania of 4.0 
and a NNT for the prevention of depression of 2.0 would have a 
PI = 2.0, whereas a drug with a NNT for the prevention of mania 
of 8.0 and a NNT for the prevention of depression of 2.5 would 
have the same PI = 3.2. This would induce the clinician to pre-
scribe the latter drug for use in the maintenance treatment of a 
predominantly manic patient. Clearly, this choice based solely 
on the PI would be misleading. We argue here that the PI pro-
vides useful, albeit imperfect, information for the choice of a 
maintenance treatment of BD for a given patient. However, no 
metric should be used in isolation. For example, the PI should be 
used while considering the NNT and NNH (i.e. number needed 
to harm), and also taking into account the methodological qual-
ity (and risk of bias) of isolated RCTs that contributed to the 
PI, NNT, and NNH estimations. Furthermore, the calculated PI 
for divalproex and oxcarbazepine should be interpreted with 
extreme caution because pivotal trials did not evidence superi-
ority over placebo (Bowden et al., 2000; Vieta, Cruz, et al., 2008).
An important limitation of the current concept of predomi-
nant polarity (and the polarity index) refers to the fact that 
mixed episodes are not contemplated. Mixed episodes have 
been increasingly emphasized in the current nosology of BD 
(Berk et al., 2006; APA, 2013; Castle, 2014). Therefore, future stud-
ies should investigate the possible existence of a predominantly 
mixed type of BD. This awaited evolution in the concept of pre-
dominant polarity may provide a substrate to add potentially 
valuable pieces of information to the selection of the limited 
alternatives available for the treatment of mixed affective epi-
sodes (Fountoulakis et al., 2012). A first approach to this concept 
has been conducted (Pacchiarotti et al., 2011).
Conclusions
The present review concludes that the concepts of predomi-
nant polarity and polarity indexes provide clinically useful 
information for the selection of maintenance treatments for 
BD. Furthermore, there are important unanswered questions 
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for further research and this opens an important debate for the 
incorporation of these constructs in current psychiatric nosol-
ogy. If one considers clinical utility as a determinant for the 
construction of nosology, this work concludes that there prob-
ably is sufficient evidence for the incorporation of predominant 
polarity as a course specifier for BD. However, clinical trials 
(both acute and maintenance) may include the baseline deter-
mination of predominant polarity as a potential predictor of 
response. Pooled analyses would ultimately provide a stronger 
evidence base. However, there are no published studies that we 
are aware of investigating biological leads (e.g. genetic poly-
morphisms, neuropsychological tests, and neuroimaging cor-
relates) related to predominant polarity. Considering emerging 
neuroscience-based models of psychiatric nosology (such as the 
National Institute of Mental Health Research Domain Criteria), 
further investigations are needed in this particular field (Insel 
et al., 2010; Cuthbert and Insel, 2013).
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